[go: up one dir, main page]

WO2007038868A3 - Novel enediyne compound and uses thereof - Google Patents

Novel enediyne compound and uses thereof Download PDF

Info

Publication number
WO2007038868A3
WO2007038868A3 PCT/CA2006/001634 CA2006001634W WO2007038868A3 WO 2007038868 A3 WO2007038868 A3 WO 2007038868A3 CA 2006001634 W CA2006001634 W CA 2006001634W WO 2007038868 A3 WO2007038868 A3 WO 2007038868A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
uncialamycin
methods
compound
kill
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2006/001634
Other languages
French (fr)
Other versions
WO2007038868A2 (en
Inventor
Julian E Davies
Raymond J Anderson
Hao Wang
Koaru Warabi
Xin Hui Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of WO2007038868A2 publication Critical patent/WO2007038868A2/en
Publication of WO2007038868A3 publication Critical patent/WO2007038868A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a novel enediyne compound, uncialamycin, including analogues thereof. The invention also relates to methods of using the compound to treat bacterial infections, to inhibit bacterial growth, and to kill bacteria. This invention may also be used to treat tumors, to prevent growth of tumor cells, to kill tumor cells, to treat cancers, to prevent growth of cancer cells, and to kill cancer cells. The invention also relates to methods of making analogues of uncialamycin. The invention also relates to compositions comprising uncialamycin and methods of administering the compositions.
PCT/CA2006/001634 2005-10-03 2006-10-03 Novel enediyne compound and uses thereof Ceased WO2007038868A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72240705P 2005-10-03 2005-10-03
US60/722,407 2005-10-03

Publications (2)

Publication Number Publication Date
WO2007038868A2 WO2007038868A2 (en) 2007-04-12
WO2007038868A3 true WO2007038868A3 (en) 2007-11-08

Family

ID=37906518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2006/001634 Ceased WO2007038868A2 (en) 2005-10-03 2006-10-03 Novel enediyne compound and uses thereof

Country Status (1)

Country Link
WO (1) WO2007038868A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101660146B1 (en) * 2012-02-13 2016-09-26 브리스톨-마이어스 스큅 컴퍼니 Enediyne compounds, conjugates thereof, and uses and methods therefor
US9777013B2 (en) * 2013-08-14 2017-10-03 William Marsh Rice University Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
EP3647322B1 (en) 2014-03-20 2021-10-20 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
SG10201913004UA (en) 2014-11-21 2020-03-30 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
SMT202000579T1 (en) 2014-11-21 2020-11-10 Bristol Myers Squibb Co Antibodies comprising modified heavy constant regions
JP6622814B2 (en) 2014-11-25 2019-12-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Novel PD-L1 binding polypeptides for imaging
US10336766B2 (en) * 2015-01-08 2019-07-02 The Scripps Research Institute Anticancer drug candidates
ES2736106T3 (en) 2015-03-10 2019-12-26 Bristol Myers Squibb Co Antibodies that can be conjugated by transglutaminase and conjugates produced from them
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
JP6990650B2 (en) * 2015-09-17 2022-03-04 ザ スクリプス リサーチ インスティテュート Double variable domain immunoconjugate and its uses
EP3733698A1 (en) 2015-09-23 2020-11-04 Bristol-Myers Squibb Company Glypican-3 binding fibronectin based scafflold molecules
BR112018012524A2 (en) 2015-12-21 2018-12-11 Bristol Myers Squibb Co variant antibodies for site-specific conjugation
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
KR20240149979A (en) 2017-05-25 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 Antibodies comprising modified heavy constant regions
CN113348177A (en) 2018-11-28 2021-09-03 百时美施贵宝公司 Antibodies comprising modified heavy chain constant regions
SI3886914T1 (en) 2018-11-30 2023-06-30 Bristol-Myers Squibb Company Antibody comprising a glutamine-containing light chain c-terminal extension, conjugates thereof, and methods and uses
JP7514836B2 (en) 2018-12-12 2024-07-11 ブリストル－マイヤーズ スクイブ カンパニー Engineered antibodies for conjugation with transglutaminase, and conjugates, methods and uses thereof
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
CN116813627B (en) * 2023-06-15 2025-08-12 哈药慈航制药股份有限公司 A Tiancimycin analogue and its preparation method and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849750A (en) * 1994-07-27 1998-12-15 California Institute Of Technology Dynemicin analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849750A (en) * 1994-07-27 1998-12-15 California Institute Of Technology Dynemicin analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVIES ET AL.: "UNCIALAMYCIN, A NEW ENEDIYNE ANTIBIOTIC", ORGANIC LETTERS, vol. 7, no. 23, 13 October 2005 (2005-10-13), pages 5233 - 5236, XP055154051, DOI: doi:10.1021/ol052081f *

Also Published As

Publication number Publication date
WO2007038868A2 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
WO2007038868A3 (en) Novel enediyne compound and uses thereof
MX2007002398A (en) New pharmaceutical compositions for the treatment of cancer.
WO2007011962A3 (en) Treatment of cancer
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MX361467B (en) Isoindoline compounds for use in the treatment of cancer.
WO2006037024A3 (en) Salts of decitabine
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
MX2009006742A (en) Novel compounds.
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
IL164509A0 (en) Furyl compounds
TW200738234A (en) Triazole compounds that modulate HSP90 activity
TNSN07294A1 (en) Treatment of metastasized tumors
MX2008015775A (en) Compounds and compositions for treatment of cancer.
WO2005037839A8 (en) Norcantharidin derivative compounds, method for the production thereof, compositions containing said compounds and the use thereof
MX2007013624A (en) Protein kinase inhibitors.
WO2005030794A3 (en) Hemiasterlin derivatives and uses thereof
WO2006125555A3 (en) Quinazolinones
WO2008072952A3 (en) Anti-inflammatory compounds containing compositions for treatment of cancer
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
TW200504051A (en) Novel acridine derivatives and their use as medicaments
WO2010093615A3 (en) Compounds, their syntheses, compositions, and methods to treat cancer
WO2010075255A3 (en) Methods for treating or preventing cancer and neurodegenerative diseases

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06790794

Country of ref document: EP

Kind code of ref document: A2